NY-ESO-1 expression and immunogenicity in malignant and benign breast tumors Journal Article


Authors: Sugita, Y.; Wada, H.; Fujita, S.; Nakata, T.; Sato, S.; Noguchi, Y.; Jungbluth, A. A.; Yamaguchi, M.; Chen, Y. T.; Stockert, E.; Gnjatic, S.; Williamson, B.; Scanlan, M. J.; Ono, T.; Sakita, I.; Yasui, M.; Miyoshi, Y.; Tamaki, Y.; Matsuura, N.; Noguchi, S.; Old, L. J.; Nakayama, E.; Monden, M.
Article Title: NY-ESO-1 expression and immunogenicity in malignant and benign breast tumors
Abstract: NY-ESO-1 is a cancer/testis antigen expressed in normal adult tissues solely in the testicular germ cells of normal adults and in various cancers. It induces specific humoral and cellular immunity in patients with NY-ESO-1-expressing cancer. The aim of this study was to determine the frequency of NY-ESO-1 mRNA and protein expression in malignant and benign breast tumors. NY-ESO-1 mRNA expression was detected by conventional reverse transcription-PCR and real-time PCR, and that of the protein expression by immunohistochemistry and Western blot analysis. Expression of NY-ESO-1 mRNA was detected in 37 of 88 (42%) cancer specimens, whereas that of the NY-ESO-1 protein was detected only in 1 mRNA-positive specimen. In the latter case, expression level of NY-ESO-1 mRNA relative to that in the testis was relatively high (75% of testicular expression) and to the other among breast cancer specimens. In benign breast lesions, 21 of 31 (68%) specimens expressed low levels of NY-ESO-1 mRNA. In 1 case of fibroadenoma, NY-ESO-1 mRNA was 8% of the testicular level, and protein was detected by Western blot analysis. Only 1 breast cancer patient had detectable antibody at time of surgery, which disappeared within 2 years. Tumor specimen from this patient was both NY-ESO-1 mRNA and protein positive, and NY-ESO-1-specific CD8 T cells were detected in this patient by IFN-γ enzyme-linked immunospot assay using NY-ESO-1 recombinant adeno and vaccinia virus. A higher rate of NY-ESO-1 expression was noted in breast cancer with high histological grade and negative hormone receptor status, suggesting NY-ESO-1 as a potential tumor antigen for immunotherapy in patients with breast cancer and poor prognosis.
Keywords: immunohistochemistry; adult; controlled study; human tissue; protein expression; unclassified drug; human cell; major clinical study; histopathology; protein localization; cd8 antigen; antigen expression; t lymphocyte; cd8-positive t-lymphocytes; cancer immunotherapy; reverse transcription polymerase chain reaction; breast cancer; germ cell; membrane proteins; transfection; breast neoplasms; tumor antigen; gene expression regulation, neoplastic; cellular immunity; antigens, neoplasm; messenger rna; reverse transcriptase polymerase chain reaction; rna, messenger; ny eso 1 antigen; immunogenicity; recombinant proteins; western blotting; vaccinia virus; receptors, estrogen; neoplasm invasiveness; enzyme-linked immunosorbent assay; enzyme linked immunospot assay; humoral immunity; fibroadenoma; antibodies, neoplasm; testis; lymphocyte depletion; carcinoma, ductal; adenoviridae; adenovirus; humans; prognosis; human; male; female; priority journal; article
Journal Title: Cancer Research
Volume: 64
Issue: 6
ISSN: 0008-5472
Publisher: American Association for Cancer Research  
Date Published: 2004-03-15
Start Page: 2199
End Page: 2204
Language: English
DOI: 10.1158/0008-5472.can-03-3070
PROVIDER: scopus
PUBMED: 15026363
DOI/URL:
Notes: Cancer Res. -- Cited By (since 1996):58 -- Export Date: 16 June 2014 -- CODEN: CNREA -- Source: Scopus
Altmetric Score
MSK Authors
  1. Matthew J Scanlan
    48 Scanlan
  2. Sacha Gnjatic
    111 Gnjatic
  3. Achim Jungbluth
    340 Jungbluth
  4. Lloyd J Old
    385 Old